Histopathologic and clinical features of medullary microcarcinoma and C-cell hyperplasia in prophylactic thyroidectomies for medullary carcinoma: A study of 42 cases

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 11, 2008, Pages 1767-1773

  Etit, Demet ^a,d   Faquin, William C ^a,b   Gaz, Randall ^a,b   Randolph, Gregory ^a,b   DeLellis, Ronald A ^c   Pilch, Ben Z ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CALCITONIN; EOSIN; HEMATOXYLIN;

ADOLESCENT; ADULT; AGED; ARTICLE; C CELL HYPERPLASIA; CALCITONIN BLOOD LEVEL; CELL HYPERPLASIA; CHILD; CLINICAL ARTICLE; EXON; FEMALE; GENE MUTATION; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MEDULLARY CARCINOMA; MEDULLARY MICROCARCINOMA; MORPHOLOGY; PROGNOSIS; PROTO ONCOGENE; STROMA CELL; THYROID CANCER; THYROIDECTOMY;

EID: 55549137395     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.1043/1543-2165-132.11.1767     Document Type: Article

References (41)

1. DeLellis R. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662-669.
2. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:1105-1113.
3. Roman S, Lin R, Sosa J. Prognosis of medullary thyroid carcinoma: demographic, clinical, pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134-2142.
4. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol. 1998;48:265-273.
5. Kaserer K, Scheuba C, Neuhold N, et al. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol. 2001;25:1245-1251.
6. Kaserer K, Scheuba C, Neuhold N, et al. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. Am J Surg Pathol. 1998;22:722-728.
7. Guyétant S, Josselin N, Savagner F, et al. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Mod Pathol. 2003;16:756-763.
8. Krueger JE, Maitra A, Albores-Saavedra J. Inherited medullary microcarcinoma of the thyroid: a study of 11 cases. Am J Surg Pathol. 2000;24:853-858.
9. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375-376.
10. Vierhapper H, Bieglmayer C, Heinze G, et al. Frequency of RET protooncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. Thyroid. 2004;14:580-583.
11. Fink M, Weinhüsel A, Niederle B, Haas OA. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. Int J Cancer. 1996;22:69:312-316.
12. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid. Cancer. 1996;77:750-756.
13. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol. 2006;13:69-75.
14. Guyétant S, Dupre F, Bigorgne JC, et al. Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease. Hum Pathol. 1999;30:957-963.
15. You YN, Lakhani W, Wells SA, et al. Medullary thyroid cancer. Surg Oncol Clin N Am. 2006;15:639-660.
16. Carney JA. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol. 2005;29:254-274.
17. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, et al. Occult carcinoma of the thyroid: a systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022-4029.
18. Heizmann O, Haecker FM, Zumsteg U, et al. Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a. J Cancer Surg. 2006;32:98-102.
19. Hinze R, Holzhausen HJ, Gimm O, et al. Primary hereditary medullary thyroid carcinoma - C-cell morphology and correlation with preoperative calcitonin levels. Virchows Arch. 1998;433:203-208.
20. Machens A, Niccoli-Sire P, Hogel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349:1517-1525.
21. Scheuba C, Kaserer K, Weinhausl A, et al. Is medullary thyroid cancer predictable?: a prospective study of 86 patients with abnormal pentagastrin tests. Surgery. 1999;126:1089-1096.
22. Vierhapper H, Niederle B, Bieglmayer C, et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid. 2005;15:1267-1272.
23. Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg. 2007;42:326-332.
24. Chan JKC. Tumors of the thyroid and parathyroid glands. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 3rd ed. London, England: Churchill Livingstone; 2007:997-1097.
25. Bugalho JM, Domingues R, Santos JR, et al. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery. 2007;141:90-95.
26. de Groot JW, Links TP, Plukker J, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27:535-550.
27. Dourisboure RJ, Belli S, Domenichini E, et al. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma. Thyroid. 2005;15:668-671.
28. Evans DB, Shapiro SE, Cote GJ. Medullary thyroid cancer: the importance of RET testing. Surgery. 2007;141:96-99.
29. Gimm O, Ukkat J, Niederle BE, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg. 2004;28:1312-1316.
30. Gosnell JE, Sywak MS, Sidhu SB, et al. New era: prophylactic surgery for patients with multiple endocrine neoplasia 2A. ANZ J Surg. 2006;76:586-590.
31. Kitamura Y, Goodfellow PJ, Shimizu K, et al. Novel germline RET protooncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene. 1997;14:3103-3106.
32. Learoyd DL, Gosnell JE, Elston MS, et al. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol. 2005;63:636-641.
33. Machens A, Holzhausen HJ, Thanh NP, et al. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery. 2003;134:425-431.
34. Pinna G, Orgiana G, Riola A, et al. RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid. 2007;17:101-104.
35. Sanso GE, Domene HM, Garcia R, et al. Very early detection of RET protooncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer. 2002;94:323-330.
36. Szinnai G, Meier C, Komminoth P, et al. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics. 2003;111:132-139.
37. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;237-250.
38. Bergholm U, Bergström R, Ekbom A. Long term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997;79:132-138.
39. Biscolla PR, Ugolini C, Sculli M, et al. Medullary and papillary tumors are frequently associated within the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid. 2004;14:946-952.
40. Melillo RM, Cirafici AM, De Falco V, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol. 2004;165:511-521.
41. Rossi S, Fugazzola L, De Pasquale L, et al. Medullary and papillary thyroid carcinoma of the the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocr Relat Cancer. 2005;12:281-289.